{"id":"NCT02417064","sponsor":"Janssen Research & Development, LLC","briefTitle":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","officialTitle":"A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-08-10","primaryCompletion":"2018-02-20","completion":"2018-02-20","firstPosted":"2015-04-15","resultsPosted":"2019-04-18","lastUpdate":"2025-04-29"},"enrollment":346,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Treatment-resistant Depression"],"interventions":[{"type":"DRUG","name":"Esketamine","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Duloxetine (Oral Antidepressant)","otherNames":[]},{"type":"DRUG","name":"Escitalopram (Oral antidepressant)","otherNames":[]},{"type":"DRUG","name":"Sertraline (Oral Antidepressant)","otherNames":[]},{"type":"DRUG","name":"Venlafaxine Extended Release (XR) (Oral Antidepressant)","otherNames":[]}],"arms":[{"label":"Intranasal Esketamine 84mg plus Oral Antidepressant","type":"EXPERIMENTAL"},{"label":"Esketamine 56 mg plus Oral Antidepressant","type":"EXPERIMENTAL"},{"label":"Placebo plus Oral Antidepressant","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare the efficacy and safety of switching treatment-resistant depression (TRD) participants from a prior antidepressant treatment (to which they have not responded) to either intranasal esketamine plus a new oral antidepressant or switching to a new oral antidepressant plus intranasal placebo.","primaryOutcome":{"measure":"Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 of Double- Blind Induction Phase- Mixed- Effects Model Using Repeated Measures (MMRM) Analysis","timeFrame":"Baseline up to Day 28 of Double-blind Induction Phase","effectByArm":[{"arm":"Intranasal Esketamine 56 mg Plus Oral Antidepressant","deltaMin":-19,"sd":13.86},{"arm":"Intranasal Esketamine 84 mg Plus Oral AD","deltaMin":-18.8,"sd":14.12},{"arm":"Oral AD Plus Intranasal Placebo","deltaMin":-14.8,"sd":15.07}],"pValues":[{"comp":"OG001 vs OG002","p":"0.088"},{"comp":"OG000 vs OG002","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":90,"countries":["United States","Belgium","Brazil","Canada","Estonia","France","Hungary","Mexico","Slovakia"]},"refs":{"pmids":["38557430","37019044","36273682","35022754","34973081","34510411","34288609","34235612","33128208","32860422","32367114","31290965"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217051&amp;parentIdentifier=CR107146&amp;attachmentIdentifier=0cb41e2c-8076-43c1-8eb1-ae4e9fe0b016&amp;fileName=ESKETINTRD3001_(CR107146)_Additional_Results_Data_CH.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":115},"commonTop":["Nausea","Headache","Dizziness","Dissociation","Somnolence"]}}